All lobbying filings

Emergent Strategies

Emergent Strategies filed a Q4 report for Genbiopro, Inc. on January 20, 2026, reporting $35,000 in lobbying income.

Lobbying for Genbiopro, Inc. · Generic Pharmaceutical Manufacturer

As filed: EMERGENT STRATEGIES for GENBIOPRO, INC.

All filings by Emergent Strategies · Everything Genbiopro, Inc. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$35,000

What the client paid this registrant for the period.

Client based in

Nevada

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Pharmacy

FDA Approval of generic mifepristone and relate Risk Evaluation Mitigation Strategies (REMS)

Veterans

VA rule making on providing abortion services to veterans

Health Issues

Issues related to medication abortion; Issues related to abortion access

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.